Zacks Investment Research upgraded shares of Invacare (NYSE:IVC) from a sell rating to a hold rating in a research report report published on Tuesday, Zacks.com reports.

According to Zacks, “Invacare Corporation is a leading manufacturer and distributor in its markets for medical equipment used in non-acute care settings. At its core, the company designs, manufactures and distributes medical devices that help people to move, breathe, rest and perform essential hygiene. The company provides clinically complex medical device solutions for congenital (e.g., cerebral palsy, muscular dystrophy, spina bifida), acquired (e.g., stroke, spinal cord injury, traumatic brain injury, post-acute recovery, pressure ulcers) and degenerative (e.g., ALS, multiple sclerosis, chronic obstructive pulmonary disease (COPD), elderly, bariatric) ailments. The company’s products are important parts of care for people with a wide range of challenges, from those who are active and involved in work or school each day and may need additional mobility or respiratory support, to those who are cared for in residential care settings, at home and in rehabilitation centers. “

Other analysts also recently issued research reports about the stock. ValuEngine downgraded shares of Zosano Pharma from a buy rating to a hold rating in a report on Wednesday, May 1st. Needham & Company LLC reiterated a buy rating and issued a $100.00 target price on shares of LivaNova in a report on Tuesday, April 9th.

Shares of IVC stock opened at $4.89 on Tuesday. The firm has a 50-day moving average price of $5.51. The stock has a market capitalization of $165.09 million, a P/E ratio of -3.70 and a beta of 2.04. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.29 and a current ratio of 1.97. Invacare has a one year low of $3.05 and a one year high of $18.25.

Invacare (NYSE:IVC) last announced its earnings results on Monday, May 6th. The health services provider reported ($0.32) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.33) by $0.01. The company had revenue of $223.40 million during the quarter, compared to the consensus estimate of $229.93 million. Invacare had a negative net margin of 4.56% and a negative return on equity of 11.69%. The firm’s revenue for the quarter was down 5.8% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.35) earnings per share. On average, equities research analysts predict that Invacare will post -1.03 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, July 22nd. Investors of record on Friday, July 5th will be given a dividend of $0.0125 per share. The ex-dividend date of this dividend is Wednesday, July 3rd. This represents a $0.05 annualized dividend and a yield of 1.02%. Invacare’s payout ratio is currently -3.79%.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Campbell & CO Investment Adviser LLC bought a new position in shares of Invacare in the second quarter worth approximately $254,000. Crossmark Global Holdings Inc. grew its holdings in shares of Invacare by 12.5% in the second quarter. Crossmark Global Holdings Inc. now owns 28,120 shares of the health services provider’s stock worth $146,000 after purchasing an additional 3,114 shares during the last quarter. Metropolitan Life Insurance Co NY bought a new position in shares of Invacare in the first quarter worth approximately $102,000. MetLife Investment Advisors LLC bought a new position in shares of Invacare in the first quarter worth approximately $142,000. Finally, Marshall Wace LLP grew its holdings in shares of Invacare by 141.0% in the first quarter. Marshall Wace LLP now owns 973,474 shares of the health services provider’s stock worth $8,149,000 after purchasing an additional 569,509 shares during the last quarter.

Invacare Company Profile

Invacare Corporation, together with its subsidiaries, designs, manufactures, distributes, and exports medical equipment for use in home health care, retail, and extended care markets worldwide. The company operates through Europe, North America/Home Medical Equipment, Institutional Products Group, and the Asia/Pacific segments.

Further Reading: Understanding Analyst Recommendations

Get a free copy of the Zacks research report on Invacare (IVC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Invacare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invacare and related companies with MarketBeat.com's FREE daily email newsletter.